Treatment of spondyloarthritis with disease-modifying anti-rheumatic drugs during pregnancy and breastfeeding: comparing the recommendations and guidelines of the principal societies of rheumatology

被引:0
作者
Manara, M. [1 ]
Bruno, D. [2 ,3 ]
Ferrito, M. [1 ,4 ]
Perniola, S. [2 ]
Caporali, R. F. [1 ,4 ]
Gremese, E. [2 ]
机构
[1] ASST G Pini CTO, Clin Rheumatol Unit, Piazza Cardinal Ferrari 1, I-20122 Milan, Italy
[2] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Clin Immunol Unit, Rome, Italy
[3] Univ Verona, Verona, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
关键词
Axial spondyloarthritis; psoriatic arthritis; treatment; pregnancy; breastfeeding; conception; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PRESCRIBING DRUGS; BHPR GUIDELINE; WOMEN; SECUKINUMAB; MANAGEMENT; FERTILITY; INHIBITOR; HEALTH; BSR;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. This paper aims to provide an overview of the use of treatments available for axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) during pregnancy and breastfeeding, according to current national recommendations and international guidelines, as well as data on the impact on pregnancy outcomes of paternal exposure to treatment. Methods. We performed a narrative review of national and international recommendations and guidelines on the reproductive health of patients suffering from rheumatic diseases. The last updated recommendations and guidelines were considered source data. Results. We reported updated information regarding the treatment of axSpA and PsA with nonsteroidal anti-inflammatory drugs, intra-articular glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), biologic DMARDs, and targeted synthetic DMARDs during the preconception period, pregnancy, and breastfeeding, as well as data related to paternal exposure. We highlighted any medications that should be discontinued and/or not used in the reproductive age group and also treatments that may be continued, avoiding the withdrawal of drugs that can be used in the different phases, thus preventing the risk of increasing disease activity and flares before, during, and after pregnancy in SpA patients. Conclusions. The best management of pregnancy in patients with SpA is based on knowledge of updated drug recommendations, a careful and wise evaluation of the risks/benefits of starting or continuing treatment from the SpA diagnosis in a woman of childbearing age through pregnancy and lactation, and sharing therapeutic choices with other healthcare providers (in particular, gynecologists/obstetricians) and the patient.
引用
收藏
页码:222 / 231
页数:10
相关论文
共 47 条
[1]   Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare [J].
Allen, Kenneth D. ;
Kiefer, Miranda K. ;
Butnariu, Madalina ;
Afzali, Anita .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2022, 306 (06) :1929-1937
[2]   Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis [J].
Atzeni, Fabiola ;
Carriero, Antonio ;
Boccassini, Laura ;
D'Angelo, Salvatore .
IMMUNOTARGETS AND THERAPY, 2021, 10 :141-153
[3]   Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road [J].
Beltagy, Asmaa ;
Aghamajidi, Azin ;
Trespidi, Laura ;
Ossola, Wally ;
Meroni, Pier Luigi .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[4]   Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis [J].
Blauvelt, Andrew .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (02) :255-263
[5]   Fertility in women with rheumatoid arthritis: influence of disease activity and medication [J].
Brouwer, Jenny ;
Hazes, Johanna M. W. ;
Laven, Joop S. E. ;
Dolhain, Radboud J. E. M. .
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (10) :1836-1841
[6]   Sulfasalazine for ankylosing spondylitis [J].
Chen, Junmin ;
Lin, Shaopeng ;
Liu, Chao .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (11)
[7]   Methotrexate for ankylosing spondylitis [J].
Chen, Junmin ;
Veras, Mirella M. S. ;
Liu, Chao ;
Lin, Junfang .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (02)
[8]   Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 [J].
Coates, Laura C. ;
Soriano, Enrique R. ;
Corp, Nadia ;
Bertheussen, Heidi ;
Duffin, Kristina Callis ;
Campanholo, Cristiano B. ;
Chau, Jeffrey ;
Eder, Lihi ;
Fernandez-Avila, Daniel G. ;
FitzGerald, Oliver ;
Garg, Amit ;
Gladman, Dafna D. ;
Goel, Niti ;
Helliwell, Philip S. ;
Husni, M. Elaine ;
Jadon, Deepak R. ;
Katz, Arnon ;
Laheru, Dhruvkumar ;
Latella, John ;
Leung, Ying-Ying ;
Lindsay, Christine ;
Lubrano, Ennio ;
Mazzuoccolo, Luis Daniel ;
Mease, Philip J. ;
O'Sullivan, Denis ;
Ogdie, Alexis ;
Olsder, Wendy ;
Palominos, Penelope Esther ;
Schick, Lori ;
Steinkoenig, Ingrid ;
de Wit, Maarten ;
van der Windt, D. A. ;
Kavanaugh, Arthur .
NATURE REVIEWS RHEUMATOLOGY, 2022, 18 (08) :465-479
[9]   Baricitinib exposure during pregnancy in rheumatoid arthritis [J].
Costanzo, Giulia ;
Firinu, Davide ;
Losa, Francesca ;
Deidda, Margherita ;
Barca, Maria P. ;
Del Giacco, Stefano .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2020, 12
[10]   The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans [J].
Dowty, Martin E. ;
Lin, Jinyan ;
Ryder, Tim F. ;
Wang, Weiwei ;
Walker, Gregory S. ;
Vaz, Alfin ;
Chan, Gary L. ;
Krishnaswami, Sriram ;
Prakash, Chandra .
DRUG METABOLISM AND DISPOSITION, 2014, 42 (04) :759-773